Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel–based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer

BACKGROUND: Neoadjuvant chemoimmunotherapy (NCIO) is more effective than neoadjuvant immunotherapy alone for pathological response in non-small cell lung cancer (NSCLC) patients, but the processes for determining patient suitability for its implementation are not clear. We aimed to identify the most...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xingsheng, Hu, Chunhong, Liu, Xianling, Ma, Fang, Xie, Junpeng, Zhong, Ping, Tang, Chenxi, Fan, Dan, Gao, Yuan, Feng, Xiang, Ding, Mengge, Li, Dezhi, Liu, Chaoyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911863/
https://www.ncbi.nlm.nih.gov/pubmed/36776373
http://dx.doi.org/10.3389/fonc.2022.1057646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911863/
https://www.ncbi.nlm.nih.gov/pubmed/36776373
http://dx.doi.org/10.3389/fonc.2022.1057646

Ejemplares similares